ArticleRheumatology international2025
Evaluation of central sensitization and associated factors in systemic lupus erythematosus: a cross-sectional study.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Psychosocial and Functional Determinants of Central Sensitisation in Patients with Behçet's Disease: A Cross-Sectional Study.Mediterranean journal of rheumatology · 2026Article
- Evaluation of kinesiophobia, central sensitization, and related factors in patients with gout: a cross-sectional study.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To examine the central sensitization and its determinants in systemic lupus erythematosus (SLE) and compare it with psoriatic arthritis (PsA) and healthy controls (HC). We evaluated the sociodemographic and disease-related parameters, and administered to the study groups the Brief Illness Perception Questionnaire (B-IPQ), the Fatigue Severity Scale (FSS), the Jenkins Sleep Evaluation Scale (JSS), the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the Central Sensitization Inventory (CSI). We also measured pain using the visual analog scale (VAS) (0-10 cm). This study included age- and gender-matched SLE (n = 74), PsA (n = 74), and HC (n = 80) groups. The JSS, FSS, and CSI scores were higher in SLE than in HC. Although tender joint count, swollen joint count, VAS, and HAQ-DI scores were statistically higher in the PsA group compared to the SLE group, the central sensitization rates in the two groups were similar (56.7% for SLE and 55.4% for PsA, p = 0.868). CSI was significantly correlated with the number of tender joints, VAS, HAQ-DI, B-IPQ, JSS, and FSS (Spearman's rho ranged from 0.501 to 0.646) in SLE. FSS, JSS, and tender joint count were the most important predictors of CSI. Age, the number of swollen and tender joints, FSS, B-IPQ, and JSS accounted for 74% of the variation in CSI scores in SLE. Psychosocial variables influence central sensitization, which occurs frequently in SLE. SLE and PsA exhibited similar CSI scores but higher than HC. It is beneficial to evaluate and manage central sensitization in SLE patients with fatigue and sleep disorders.
Indexed as
Identifiers
41081887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.